Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2014, Article ID 486282, 6 pages
http://dx.doi.org/10.1155/2014/486282
Research Article

Serum Leptin Levels in Treatment-Naive Patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis

Department of Neurology, Eginition Hospital, Athens University Medical School, 74 Vassilisis Sophias Avenue, 11528 Athens, Greece

Received 5 September 2014; Revised 3 November 2014; Accepted 6 November 2014; Published 19 November 2014

Academic Editor: Dennis Bourdette

Copyright © 2014 Maria Eleftheria Evangelopoulos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. E. Ostlund Jr., J. W. Yang, S. Klein, and R. Gingerich, “Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates,” The Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 11, pp. 3909–3913, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. M. W. Schwartz, E. Peskind, M. Raskind, E. J. Boyko, and D. Porte Jr., “Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans,” Nature Medicine, vol. 2, no. 5, pp. 589–593, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. P. M. Moraes-Vieira, Ê. J. Bassi, R. C. Araujo, and N. O. S. Câmara, “Leptin as a link between the immune system and kidney-related diseases: leading actor or just a coadjuvant?” Obesity Reviews, vol. 13, no. 8, pp. 733–743, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Sanna, A. Di Giacomo, A. La Cava et al., “Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses,” Journal of Clinical Investigation, vol. 111, no. 2, pp. 241–250, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. A. P. Batocchi, M. Rotondi, M. Caggiula et al., “Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta,” Journal of Neuroimmunology, vol. 139, no. 1-2, pp. 150–154, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Chatzantoni, P. Papathanassopoulos, E. Gourzoulidou, and A. Mouzaki, “Leptin and its soluble receptor in plasma of patients suffering from remitting-relapsing multiple sclerosis (MS): in vitro effects of leptin on type-1 and type-2 cytokine secretion by peripheral blood mononuclear cells, T-cells and monocytes of MS patients,” Journal of Autoimmunity, vol. 23, no. 2, pp. 169–177, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Matarese, P. B. Carrieri, A. La Cava et al., “Leptin increase in multiple sclerosis associates with reduced number of CD4+CD25+ regulatory T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 14, pp. 5150–5155, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Frisullo, M. Mirabella, F. Angelucci et al., “The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis,” Journal of Neuroimmunology, vol. 192, no. 1-2, pp. 174–183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Emamgholipour, S. M. Eshaghi, A. Hossein-nezhad, K. Mirzaei, Z. Maghbooli, and M. A. Sahraian, “Adipocytokine profile, cytokine levels and foxp3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease,” PLoS ONE, vol. 8, no. 10, Article ID e76555, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Rotondi, A. P. Batocchi, F. Coperchini et al., “Severe disability in patients with relapsing-remitting multiple sclerosis is associated with profound changes in the regulation of leptin secretion,” Neuroimmunomodulation, vol. 20, no. 6, pp. 341–347, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. C. H. Polman, S. C. Reingold, G. Edan et al., “Diagnostic criteria for multiple sclerosis: 2005 Revisions to the “McDonald Criteria”,” Annals of Neurology, vol. 58, no. 6, pp. 840–846, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. W. I. McDonald, A. Compston, G. Edan et al., “Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis,” Annals of Neurology, vol. 50, no. 1, pp. 121–127, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983. View at Publisher · View at Google Scholar · View at Scopus
  14. U. Meier and A. M. Gressner, “Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin,” Clinical Chemistry, vol. 50, no. 9, pp. 1511–1525, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Gallagher, M. Visser, D. Sepúlveda, R. N. Pierson, T. Harris, and S. B. Heymsfieid, “How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups?” The American Journal of Epidemiology, vol. 143, no. 3, pp. 228–239, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. M. F. Saad, S. Damani, R. L. Gingerich et al., “Sexual dimorphism in plasma leptin concentration,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 2, pp. 579–584, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Masuzaki, Y. Ogawa, K. Hosoda et al., “Glucocorticoid regulation of leptin synthesis and secretion in humans: elevated plasma leptin levels in Cushing's syndrome,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 8, pp. 2542–2547, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Procaccini, E. Jirillo, and G. Matarese, “Leptin as an immunomodulator,” Molecular Aspects of Medicine, vol. 33, no. 1, pp. 35–45, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Matarese, A. di Giacomo, V. Sanna et al., “Requirement for leptin in the induction and progression of autoimmune encephalomyelitis,” Journal of Immunology, vol. 166, no. 10, pp. 5909–5916, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Matarese, C. Procaccini, and V. de Rosa, “The intricate interface between immune and metabolic regulation: a role for leptin in the pathogenesis of multiple sclerosis?” Journal of Leukocyte Biology, vol. 84, no. 4, pp. 893–899, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Markianos, M. E. Evangelopoulos, G. Koutsis, P. Davaki, and C. Sfagos, “Body mass index in multiple sclerosis: associations with CSF neurotransmitter metabolite levels,” ISRN Neurology, vol. 2013, Article ID 981070, 6 pages, 2013. View at Publisher · View at Google Scholar
  22. M. Stommel and C. A. Schoenborn, “Accuracy and usefulness of BMI measures based on self-reported weight and height: findings from the NHANES & NHIS 2001–2006,” BMC Public Health, vol. 9, article 421, 2009. View at Publisher · View at Google Scholar · View at Scopus